Avadel Pharmaceuticals (AVDL) EBIAT (2016 - 2021)
Historic EBIAT for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2021 value amounting to -$23.1 million.
- Avadel Pharmaceuticals' EBIAT fell 10514.28% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$88.2 million, marking a year-over-year decrease of 345346.49%. This contributed to the annual value of -$85.5 million for FY2021, which is 131721.68% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its EBIAT stood at -$23.1 million for Q4 2021, which was down 10514.28% from -$25.7 million recorded in Q3 2021.
- Avadel Pharmaceuticals' 5-year EBIAT high stood at $30.9 million for Q2 2020, and its period low was -$63.9 million during Q4 2018.
- In the last 5 years, Avadel Pharmaceuticals' EBIAT had a median value of -$10.8 million in 2020 and averaged -$7.5 million.
- Per our database at Business Quant, Avadel Pharmaceuticals' EBIAT soared by 52769.89% in 2017 and then tumbled by 67451.79% in 2018.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' EBIAT stood at -$8.2 million in 2017, then crashed by 674.52% to -$63.9 million in 2018, then skyrocketed by 95.71% to -$2.7 million in 2019, then crashed by 311.76% to -$11.3 million in 2020, then plummeted by 105.14% to -$23.1 million in 2021.
- Its last three reported values are -$23.1 million in Q4 2021, -$25.7 million for Q3 2021, and -$23.3 million during Q2 2021.